Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

In Times of COVID, We Need This ‘Recession-Proof’ Hiring Solution

During the COVID-19 pandemic, HIRE Technologies Inc. ( TSX-V: HIRE , Forum ) is proving to be highly resilient. HIRE recently achieved its best quarterly financial results with adjusted EBITDA of more than $50,000 and adjusted net earnings of more than $1...
Stockhouse Media | August 7, 2020 |

Wise investment moves to recession proof your portfolio

Robert G. Gill, senior vice president and portfolio manager at Goodreid Investment Counsel joins The Market Online to discuss recession proofing your portfolio. “A recession is an excellent time to upgrade the quality of your portfolio.”...
Coreena Robertson | September 5, 2024 |

COVID-19: A Catalyst for Small-Cap Outperformance

We believe that the COVID-19 lockdown has been a catalyst for the TSX Venture index (TSX.V) to outperform. After a decade of underperforming the major equity indices the TSX.V has led returns from the March equity market lows, gaining 58.9% as compared to 36.3% and 36.6% ...
Streetwise Reports | June 4, 2020 |

Buzz on the Bullboards: Looking for volatility-proof stocks?

This week, investors witnessed significant developments in Canadian and U.S. markets, with attention drawn to the pivotal decisions made by central banks and notable movements in key sectors. Let’s get into the highlights of the past week’s...
Jonathon Brown | April 11, 2024 |

Regeneron Reports Positive Phase 3 Dupixent Data; Gains EU Approval Recommendation

Regeneron Pharmaceuticals published positive results from two U.S. Phase 3 trials evaluating the safety and efficacy of Dupixent (dupilumab) in adults with recurring severe chronic rhinosinusitis with nasal polyps. The European Medicines Agency's Committee for Medicinal Produc...
Streetwise Reports | September 24, 2019 |

Feb 27th 2020, Crypto Chartbook – Expectations in check

Expectations in check If you compare the average performance of all major hedge funds from 1994 to 2018 you will find them underperforming the S&P by more than 2 percent. These funds cut volatility risk compared to the index by about half. However, you still can get hit h...
Korbinian Koller | February 27, 2020 |

Analyst: G1 Minimizes the Carnage of Chemotherapy

ROTH Capital Partners initiates coverage on U.S. oncology biopharma G1 Therapeutics that is now filing an NDA. In a June 26 research note, analyst Tony Butler reported that ROTH Capital Partners initiated coverage on G1 Therapeutics Inc. (GTHX:NASDAQ) with a Buy ...
Streetwise Reports | July 2, 2020 |

Buzz on the Bullboards: Can health care and energy stocks help “recession proof” your portfolio?

Investors often keep focused on the most consistent plays, when times of renewed uncertainty rears its head in the markets. The recent wave of uncertainty follows the earlier wave, both caused by the U.S. debt ceiling deal and worries over an impending rec...
Jonathon Brown | June 1, 2023 |

NervGen Pharma: Proof that NVG-291 works?

It’s arguably a Eureka moment for investors in NervGen Pharma (TSX.V: NGEN) (OTCQB: NGENF). Tantalizing anecdotal “evidence” has just been published that suggests that NervGen’s prospective wonder-drug — NVG-29...
Knox Henderson | December 23, 2024 |

XPhyto: Proof of Concept for Mescalin Synthesis

It’s become a much talked-about story on both sides of the Atlantic. XPhyto Therapeutics Corp. ( CSE: XPHY ) (FSE: 4XT) (OTCQB: XPHYF) has earned considerable media coverage in recent months due to its expansion into the development of psychedelic d...
Marc Davis | June 9, 2021 |
1 2 3 4 5 6 7 8 9 10 ...